See more : Volcanic Gold Mines Inc. (VLMZF) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESALF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Redwoods Acquisition Corp. (RWODW) Income Statement Analysis – Financial Results
- Rollins, Inc. (ROL) Income Statement Analysis – Financial Results
- Kyocera Corporation (6971.T) Income Statement Analysis – Financial Results
- Ranger Oil Corporation (ROCC) Income Statement Analysis – Financial Results
- Sovereign Diamonds Limited (SOVERDIA.BO) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESALF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 741.75B | 744.40B | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 599.49B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.48B | 431.67B | 361.84B | 302.47B |
| Cost of Revenue | 155.33B | 200.93B | 186.44B | 180.76B | 185.27B | 196.40B | 213.46B | 208.01B | 208.08B | 193.60B | 194.66B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 586.42B | 543.48B | 569.79B | 465.19B | 510.35B | 446.44B | 386.60B | 331.09B | 339.84B | 354.87B | 404.83B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.01B | 330.10B | 263.24B | 210.79B |
| Gross Profit Ratio | 79.06% | 73.01% | 75.35% | 72.02% | 73.37% | 69.45% | 64.43% | 61.42% | 62.02% | 64.70% | 67.53% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.03% | 76.47% | 72.75% | 69.69% |
| Research & Development | 169.02B | 156.69B | 158.03B | 138.82B | 125.49B | 127.63B | 131.09B | 104.27B | 110.86B | 131.91B | 136.31B | 120.38B | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 374.42B | 358.29B | 366.43B | 281.63B | 256.30B | 228.21B | 183.86B | 174.94B | 192.82B | 194.55B | 203.34B | 139.85B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | 0.00 | -10.73B | -14.29B | -11.81B | -10.11B | -9.32B | -3.94B | 671.00M | -6.95B | 0.00 | 58.22B | 68.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 374.42B | 347.56B | 352.14B | 269.82B | 246.18B | 218.89B | 179.92B | 175.61B | 185.87B | 194.55B | 203.34B | 208.73B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | -10.43B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -338.00M | 0.00 | -109.00M | -138.00M | 69.00M | 924.00M | 417.00M | -9.00M | 670.00M | 712.00M | 565.00M | 580.00M | -63.00M | 467.00M | 864.00M | 1.77B | 0.00 |
| Operating Expenses | 533.01B | 504.26B | 510.17B | 408.64B | 371.67B | 346.52B | 311.00B | 279.89B | 297.06B | 326.53B | 338.43B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.50B | 204.27B | 173.66B |
| Cost & Expenses | 688.34B | 705.18B | 696.60B | 589.40B | 556.94B | 542.91B | 524.46B | 487.89B | 505.14B | 520.13B | 533.09B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.61B | 359.06B | 302.88B | 265.34B |
| Interest Income | 10.80B | 4.62B | 1.68B | 1.30B | 3.26B | 4.16B | 1.75B | 1.08B | 1.20B | 2.43B | 1.79B | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.44B | 3.19B | 0.00 |
| Interest Expense | 2.39B | 2.27B | 1.69B | 1.19B | 1.17B | 1.46B | 2.83B | 2.78B | 3.46B | 4.89B | 5.89B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 39.40B | 39.98B | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 39.93B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.36B | 18.49B | 17.97B | 17.97B | 15.00B | 15.14B |
| EBITDA | 103.61B | 79.20B | 94.55B | 89.42B | 163.23B | 117.85B | 101.78B | 77.69B | 76.84B | 69.71B | 108.12B | 129.21B | 150.23B | 161.25B | 144.72B | 136.75B | 52.81B | 137.20B | 121.15B | 110.06B | 101.88B | 94.16B | 81.02B | 78.93B | 41.81B |
| EBITDA Ratio | 13.97% | 10.64% | 12.96% | 14.37% | 24.78% | 19.72% | 16.96% | 14.41% | 14.02% | 12.71% | 18.03% | 21.84% | 22.47% | 21.31% | 18.02% | 19.04% | 7.35% | 20.35% | 20.82% | 20.91% | 20.37% | 20.19% | 18.55% | 21.81% | 13.16% |
| Operating Income | 53.41B | 39.22B | 59.62B | 56.54B | 138.68B | 99.92B | 75.60B | 51.21B | 42.78B | 28.34B | 66.40B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.20% | 5.27% | 7.88% | 8.75% | 19.94% | 15.54% | 12.60% | 9.50% | 7.81% | 5.17% | 11.08% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | 8.42B | 4.97B | 708.00M | 1.04B | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -4.10B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 61.82B | 45.01B | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 62.30B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 8.33% | 6.05% | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 10.39% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.97% | 14.54% | 11.84% | 8.44% |
| Income Tax Expense | 18.04B | -11.82B | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 23.80B | 22.88B | 35.71B | 34.79B | 33.42B | 22.14B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | 28.61B | -26.10B | 19.63B | 14.20B |
| Net Income | 42.41B | 55.43B | 47.95B | 41.94B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 38.25B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.51B | 23.09B | 11.28B |
| Net Income Ratio | 5.72% | 7.45% | 6.34% | 6.49% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 6.38% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.80% | 8.46% | 6.38% | 3.73% |
| EPS | 147.86 | 193.31 | 167.27 | 146.95 | 425.01 | 221.34 | 181.18 | 137.62 | 192.23 | 606.28 | 536.52 | 677.52 | 821.32 | 946.08 | 566.32 | 669.40 | -239.20 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| EPS Diluted | 147.86 | 193.30 | 167.25 | 146.90 | 424.80 | 221.12 | 180.97 | 137.41 | 191.76 | 605.48 | 536.04 | 677.24 | 821.24 | 946.04 | 566.24 | 669.20 | -239.20 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| Weighted Avg Shares Out | 286.80M | 286.76M | 286.69M | 286.62M | 286.51M | 286.37M | 286.16M | 285.98M | 285.76M | 71.44M | 71.34M | 71.25M | 71.24M | 71.23M | 71.23M | 71.23M | 71.12M | 71.23M | 71.47M | 71.45M | 71.94M | 74.14M | 72.93M | 74.11M | 74.11M |
| Weighted Avg Shares Out (Dil) | 286.80M | 286.76M | 286.73M | 286.71M | 286.65M | 286.66M | 286.48M | 286.42M | 286.47M | 71.62M | 71.44M | 71.25M | 71.24M | 71.24M | 71.24M | 71.25M | 71.12M | 71.23M | 71.47M | 71.45M | 71.94M | 74.14M | 72.93M | 74.11M | 74.11M |
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
Source: https://incomestatements.info
Category: Stock Reports